Biography and Research Information

OverviewAI-generated summary

Amal Shoeib's research focuses on investigating cannabinoid receptors as potential targets for anti-cancer drug development. This work includes the synthesis, molecular pharmacology, and structure-activity relationships of compounds designed to selectively antagonize cannabinoid type 2 receptors. Publications detail the characterization of these receptors in specific cancer cell lines, such as Ewing sarcoma, and explore how natural and synthetic cannabinoids can reduce cancer cell viability, potentially through non-canonical receptor interactions. Shoeib has published 10 papers, with an h-index of 5 and 69 total citations. Key collaborators at the University of Arkansas for Medical Sciences include Shengyu Mu, Alicja Urbaniak, Azure L. Yarbrough, and Anna Radomińska‐Pandya, with whom Shoeib has co-authored multiple publications.

Metrics

  • h-index: 5
  • Publications: 10
  • Citations: 69

Selected Publications

  • Non-Canonical Cannabinoid Receptors with Distinct Binding and Signaling Properties in Prostate and Other Cancer Cell Types Mediate Cell Death (2022) DOI
  • Characterization of cannabinoid receptors expressed in Ewing sarcoma TC-71 and A-673 cells as potential targets for anti-cancer drug development (2021) DOI
  • Natural and Synthetic Cannabinoids Reduce Cell Viability of Ewing Sarcoma TC‐71 Cells Potentially via Non‐canonical CB receptors (2021) DOI
  • Synthesis, Molecular Pharmacology, and Structure–Activity Relationships of 3-(Indanoyl)indoles as Selective Cannabinoid Type 2 Receptor Antagonists (2021) DOI

Collaborators

Researchers in the database who share publications

Similar Researchers

Based on overlapping research topics